Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Mylan launches Advair generic at 70% discount in USMylan has launched its generic version of GlaxoSmithKline’s respiratory blockbuster, Advair, at a 70% discount compared with the Share XMylan launches Advair generic at 70% discount in UShttps://pharmaphorum.com/news/mylan-launches-advair-generic-at-70-discount-in-us/
Circassia prepares for potential US launch of nitric oxide productUK biotech Circassia has said that its partner AIT Therapeutics has held a meeting with the FDA that Share XCircassia prepares for potential US launch of nitric oxide producthttps://pharmaphorum.com/news/circassia-prepares-for-potential-us-launch-of-nitric-oxide-product/
FDA finally approves Mylan’s Advair genericThe FDA has finally approved the first generic of GlaxoSmithKline’s Advair blockbuster respiratory diseases inhaler, after years of Share XFDA finally approves Mylan’s Advair generichttps://pharmaphorum.com/news/fda-finally-approves-mylans-advair-generic/
AZ’s new COPD inhaler Bevespi Aerosphere approved in EUAstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic Share XAZ’s new COPD inhaler Bevespi Aerosphere approved in EUhttps://pharmaphorum.com/news/astrazeneca-copd-bevespi-aerosphere/
Vectura takes £40 million hit as asthma drug fails trialVectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting Share XVectura takes £40 million hit as asthma drug fails trialhttps://pharmaphorum.com/news/vectura-takes-40-million-hit-as-asthma-drug-fails-trial/
Roche aims to extend shelf life of Xolair with new prefilled pen formulationThe FDA has approved a new prefilled syringe formulation for Roche’s asthma drug Xolair, as the Swiss company Share XRoche aims to extend shelf life of Xolair with new prefilled pen formulationhttps://pharmaphorum.com/news/roche-aims-to-extend-shelf-life-of-xolair-with-new-prefilled-pen-formulation/
CSL Behring lung drug would cost NHS £8m per patient, says NICENICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it Share XCSL Behring lung drug would cost NHS £8m per patient, says NICEhttps://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/
AZ COPD drug fails to match GSK rival after disappointing launchAstraZeneca has said it is analysing “inconsistent” results after a late-stage trial of its Bevespi Aerosphere inhaler in Share XAZ COPD drug fails to match GSK rival after disappointing launchhttps://pharmaphorum.com/news/az-copd-drug-fails-match-gsk-rival/
